重组人脑钠利肽对缺血性心肌病心力衰竭NT-proBNP和6MWT及心功能改善的影响

Effects of recombinant human brain natriuretic peptide on improvement of heart function and NT-probNP and 6MWT in ischemic cardiomyopathy with heart failure

目的分析缺血性心肌病心力衰竭患者联合应用重组人脑钠利肽与左西孟旦治疗的心功能改善与血浆氨基末端脑钠肽前体(NT-proBNP)、6分钟步行试验(6MWT)的变化。方法选取80例2018年6月至2020年12月郑州市第七人民医院接受治疗的缺血性心肌病心力衰竭患者,随机分为两组,在实施常规治疗的同时,对照组单纯给予左西孟旦治疗,研究组在对照组基础上加用重组人脑钠利肽治疗,比较两组心功能改善与NT-proBNP、6MWT水平。结果研究组治疗有效率为95.0%,显著高于对照组的75.0%,差异有统计学意义(P<0.05),研究组治疗后的LVEF为(46.2±5.5)%、NT-proBNP为(1 236.4±45.8)pg/ml, LVEDD为(45.6±4.7)mm, 6MWT为(525.6±49.3)m,与对照组各指标比较差异均具有统计学意义(P<0.05)。两组不良反应差异无统计学意义(P>0.05)。结论重组人脑钠利肽与左西孟旦联合应用,能够有效缓解缺血性心肌病心力衰竭患者症状,改善患者心功能,临床效果显著,且安全性高,值得推广。

Objective To analyze the improvement of cardiac function in patients with heart failure of ischemic cardiomyopathy treated with recombinant human brain natriuretic peptide combined with Levosimendan and the changes of plasma amino-terminal brain natriuretic peptide precursor(NT-probNP) and six-minute walking test(6 MWT). Methods Chose 80 cases between June 2018 to December 2020 in our hospital for treatment of ischemic cardiomyopathy heart failure patients, randomly divided into two groups, in the implementation of regular treatment at the same time, the control group simply given Leosimendan treatment, patients in the control group on the basis of plus sodium with recombinant human brain peptide treatment, compared two groups of cardiac function improvement and the NT-proBNP and level 6 MWT. Results The treatment efficiency of the study group was 95.0%, significantly higher than the 75.0% of the control group(P<0.05). After treatment, the LVEF of the study group was(46.2±5.5) %, NT-probNP was(1 236.4±45.8) pg/mL, LVEDD was(45.6±4.7) mm, and 6 MWT was(525.6±49.3) m, with significant differences of the control group(P<0.05). There was no significant difference in adverse reactions between the two groups(P>0.05). Conclusion The combined application of recombinant human brain natriuretic peptide and Levosimendan can effectively alleviate the symptoms and improve the cardiac function in patients with ischemic cardiomyopathy with high safety, which is worth promoting.